Switzerland · Research startup
Switzerland · Numab Therapeutics AG
Numab Therapeutics AG is a clinical-stage biotechnology company based in Horgen, Switzerland, founded in 2011.
Funding reportedLast round: Series C
About Numab Therapeutics AG
Numab Therapeutics AG is a clinical-stage biotechnology company based in Horgen, Switzerland, founded in 2011.
The company focuses on developing multi-specific antibody-based immunotherapies for inflammation and cancer, utilizing its proprietary platforms, λ-CapTM and MATCHTM. Numab aims to create first-in-class and best-in-class medicines that enhance patient outcomes through a reproducible therapeutic design process. The company specializes in oncology and inflammatory diseases, targeting non-traditional antibody targets, including complex membrane proteins. Numab's pipeline includes innovative assets like NM26, a bispecific antibody for atopic dermatitis, and NM32, a T-cell engager for solid tumors and hematological malignancies. In addition to its internal drug development, Numab offers discovery and development services to industry partners, including technology licensing and custom therapeutics. With over $223 million raised in funding, Numab is well-positioned to advance its mission in the biopharmaceutical landscape.
What company datasets say Numab Therapeutics AG raised
Funding, as reported
Founders and team
From Numab Therapeutics AG's own website: 12 on the team.
- Barbara AngehrnChief Executive Officer
- Alain BertalloVice President, People & Culture
- Andrew FoxSenior Vice President, Development Operations
- James SingletonChief Legal Officer
- Raj ChopraChief Scientific Officer
- Stefan WarmuthChief Technology Officer
- Uyum EvcinHead of Business Development
- Carlo IncertiChairman of the Board
- David UrechDirector, R&D Committee Chair
- Matthias FehrDirector, Audit & Risk Committee Chair
- Michael K. BauerDirector, Compensation Committee Chair
- Oliver MiddendorpDirector
On a portfolio page
Investors who name them
Each firm lists Numab Therapeutics AG on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
biotechnology researchb2b
Built with from their website
Microsoft ExchangeMicrosoft 365 Apps & ServicesMicrosoft Exchange OnlineMicrosoft 365OutlookMicrosoft Email Providers
- Sector
- Research
- Industry code
- NAICS 541714, 325414, SIC 2834
- Region
- Zurich
- Revenue
- 17.1M a year, as listed
Research in Switzerland
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Numab Therapeutics AG in front of investors. Or tell us what we have wrong.